Cipla500087Pharmaceuticals
Cipla's Q2 results disappointed street with profit and revenue missing estimates, though margins beat expectations
By ScoutQuest · · 1 min read
- Profit decline YoY
- 35 percent
- Revenue decline YoY
- 2 percent
- EBITDA margin
- 18.7 percent
- India business growth
- 12 percent
- US revenue
- 172 million dollars
Heard on business television between 14:42:20 - 14:45:20 IST.
- Profit fell 35% year-on-year due to lower other income, missing street estimates.
- Revenue was down almost 2% versus expectation of 0.6% growth.
- EBITDA margin came at around 18.7% versus expectation of around 18%, a slight beat.
- India business grew 12% year-on-year versus street expectation of 13-14%, still the highest ever quarterly India sales.
- US revenue came at $172 million, down 19% year-on-year versus estimate of $170-180 million, due to Revlimid erosion; Europe in line, Africa soft as expected; stock down almost 1% in trade.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Cipla
Cipla reported modest Q2 numbers but maintained its US revenue and EBITDA margin guidance, prompting mixed brokerage reactions
28 Oct 2026
Cipla posts audio recording of Q2/H1 FY27 earnings conference call on its website
27 Oct 2026
Cipla's Q2 results were largely in line with estimates, with a dip in profit and muted US sales due to supply issues
27 Oct 2026
Source: Live TV News Channel · 27 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.